Show simple item record

dc.contributor.authorGupta, RKen_US
dc.contributor.authorCalderwood, CJen_US
dc.contributor.authorYavlinsky, Aen_US
dc.contributor.authorKrutikov, Men_US
dc.contributor.authorQuartagno, Men_US
dc.contributor.authorAichelburg, MCen_US
dc.contributor.authorAltet, Nen_US
dc.contributor.authorDiel, Ren_US
dc.contributor.authorDobler, CCen_US
dc.contributor.authorDominguez, Jen_US
dc.contributor.authorDoyle, JSen_US
dc.contributor.authorErkens, Cen_US
dc.contributor.authorGeis, Sen_US
dc.contributor.authorHaldar, Pen_US
dc.contributor.authorHauri, AMen_US
dc.contributor.authorHermansen, Ten_US
dc.contributor.authorJohnston, JCen_US
dc.contributor.authorLange, Cen_US
dc.contributor.authorLange, Ben_US
dc.contributor.authorvan Leth, Fen_US
dc.contributor.authorMuñoz, Len_US
dc.contributor.authorRoder, Cen_US
dc.contributor.authorRomanowski, Ken_US
dc.contributor.authorRoth, Den_US
dc.contributor.authorSester, Men_US
dc.contributor.authorSloot, Ren_US
dc.contributor.authorSotgiu, Gen_US
dc.contributor.authorWoltmann, Gen_US
dc.contributor.authorYoshiyama, Ten_US
dc.contributor.authorZellweger, J-Pen_US
dc.contributor.authorZenner, Den_US
dc.contributor.authorAldridge, RWen_US
dc.contributor.authorCopas, Aen_US
dc.contributor.authorRangaka, MXen_US
dc.contributor.authorLipman, Men_US
dc.contributor.authorNoursadeghi, Men_US
dc.contributor.authorAbubakar, Ien_US
dc.date.accessioned2020-10-26T11:33:14Z
dc.date.available2020-08-27en_US
dc.date.issued2020-10-19en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/67779
dc.description.abstractThe risk of tuberculosis (TB) is variable among individuals with latent Mycobacterium tuberculosis infection (LTBI), but validated estimates of personalized risk are lacking. In pooled data from 18 systematically identified cohort studies from 20 countries, including 80,468 individuals tested for LTBI, 5-year cumulative incident TB risk among people with untreated LTBI was 15.6% (95% confidence interval (CI), 8.0-29.2%) among child contacts, 4.8% (95% CI, 3.0-7.7%) among adult contacts, 5.0% (95% CI, 1.6-14.5%) among migrants and 4.8% (95% CI, 1.5-14.3%) among immunocompromised groups. We confirmed highly variable estimates within risk groups, necessitating an individualized approach to risk stratification. Therefore, we developed a personalized risk predictor for incident TB (PERISKOPE-TB) that combines a quantitative measure of T cell sensitization and clinical covariates. Internal-external cross-validation of the model demonstrated a random effects meta-analysis C-statistic of 0.88 (95% CI, 0.82-0.93) for incident TB. In decision curve analysis, the model demonstrated clinical utility for targeting preventative treatment, compared to treating all, or no, people with LTBI. We challenge the current crude approach to TB risk estimation among people with LTBI in favor of our evidence-based and patient-centered method, in settings aiming for pre-elimination worldwide.en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofNat Meden_US
dc.titleDiscovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.en_US
dc.typeArticle
dc.identifier.doi10.1038/s41591-020-1076-0en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33077958en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
dcterms.dateAccepted2020-08-26en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record